TY - JOUR
TI - Expression of syndecan-1 in chronic liver diseases: Correlation with hepatic fibrosis
AU - Charchanti, A.
AU - Kanavaros, P.
AU - Koniaris, E.
AU - Kataki, A.
AU - Glantzounis, G.
AU - Agnantis, N.J.
AU - Goussia, A.C.
JO - In vivo (Athens, Greece)
PY - 2021
VL - 35
TODO - 1
SP - 333-339
PB - International Institute of Anticancer Research
SN - null
TODO - 10.21873/INVIVO.12264
TODO - syndecan 1;  membrane protein;  syndecan 1, adolescent;  adult;  aged;  Article;  chronic liver disease;  controlled study;  correlation analysis;  female;  fibrogenesis;  human;  human tissue;  immunohistochemistry;  liver biopsy;  liver fibrosis;  major clinical study;  male;  pathogenesis;  protein expression;  staging;  tissue section;  very elderly;  genetics;  immunohistochemistry;  liver cirrhosis, Humans;  Immunohistochemistry;  Liver Cirrhosis;  Membrane Glycoproteins;  Syndecan-1
TODO - Background/Aim: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. Materials and Methods: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. Results: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis. Conclusion: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis. © 2021 International Institute of Anticancer Research. All rights reserved.
ER -